New AI tool accurately portrays metabolic states
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
List view / Grid view
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
Using its AI-driven platform, Pepper Bio discovered a promising therapeutic for liver cancer. In this Q&A session with Jon Hu, CEO and co-founder of Pepper Bio, we dive into how the identification of two inhibitors led to a $135M in-licensing deal.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
Researchers highlight the need for considering biomarkers alongside other health outcomes, as well as the need for omic data standardisation.
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
Data from protein analyses, combined with data from patient journals, enabled the discovery of proteins that predict disease progression.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.